Personalized Inhaled Bacteriophage Therapy Decreases Multidrug-Resistant Pseudomonas aeruginosa

No abstract is available for this paper.

• Publication year

  2023

• Venue

  medRxiv

• Publication date

  2023-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1101/2023.01.23.22283996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Mitigation of evolved bacterial resistance to phage therapy.

  2022cited by this paper
• Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection

  2021cited by this paper
• The determinants of survival among adults with cystic fibrosis—a cohort study

  2021cited by this paper
• Advancing phage therapy through the lens of virus host-breadth and emergence potential.

  2021cited by this paper
• SPLUNC1: a novel marker of cystic fibrosis exacerbations

  2020cited by this paper
• Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance

  2020cited by this paper
• Antimicrobial Resistance in ESKAPE Pathogens

  2020cited by this paper
• Bacteriophage therapy for infections in CF

  2020cited by this paper
• High-throughput discovery of phage receptors using transposon insertion sequencing of bacteria

  2020cited by this paper
• Engineered bacteriophages for treatment of a patient with a disseminated drug resistant Mycobacterium abscessus

  2019cited by this paper
• Quantitative Models of Phage-Antibiotic Combination Therapy

  2019cited by this paper
• Resistance Evolution against Phage Combinations Depends on the Timing and Order of Exposure

  2019cited by this paper
• Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria.

  2019cited by this paper
• Phage treatment of an aortic graft infected with Pseudomonas aeruginosa

  2018cited by this paper
• Cross-resistance is modular in bacteria–phage interactions

  2018cited by this paper
• Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children

  2018cited by this paper
• Database resources of the National Center for Biotechnology Information

  2017cited by this paper
• Pseudomonas aeruginosa Contact-Dependent Growth Inhibition Plays Dual Role in Host-Pathogen Interactions

  2017cited by this paper
• Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa

  2016cited by this paper
• Lipopolysaccharide modification in Gram-negative bacteria during chronic infection.

  2016cited by this paper
• Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response

  2015cited by this paper
• Antimicrobial bacteriophage-derived proteins and therapeutic applications

  2015cited by this paper
• Biogeochemical Forces Shape the Composition and Physiology of Polymicrobial Communities in the Cystic Fibrosis Lung

  2014cited by this paper
• Evaluation of lytic activity of staphylococcal bacteriophage Sb‐1 against freshly isolated clinical pathogens

  2011cited by this paper
• Phage therapy experience at the Eliava Institute.

  2008cited by this paper
• Escape from Prisoner's Dilemma in RNA phage phi6.

  2003cited by this paper
• Type IV pili and twitching motility.

  2002cited by this paper
• Prisoner's dilemma in an RNA virus

  1999cited by this paper
• CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells.

  1994cited by this paper
• Gene Flow in Natural Populations

  1985cited by this paper
• [Considerations on the treatment of common respiratory diseases by means of bacteriophages].

  1959cited by this paper
• “Annual Review of Microbiology”

  1946cited by this paper
• Evolution in Mendelian Populations.

  1931cited by this paper

• Bacterial Receptors but Not Anti-Phage Defense Mechanisms Determine Host Range for a Pair of Pseudomonas aeruginosa Lytic Phages

  2026cites this paper
• Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States

  2025cites this paper
• Clinical Application of Bacteriophage Therapy in Children.

  2025cites this paper
• The contribution of neutrophils to bacteriophage clearance and pharmacokinetics in vivo

  2024cites this paper
• A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections

  2024cites this paper
• Lytic bacteriophages induce the secretion of antiviral and proinflammatory cytokines from human respiratory epithelial cells

  2024cites this paper
• Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University

  2024cites this paper
• Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients.

  2024cites this paper
• Microscopic Phage Adsorption Assay: High-throughput quantification of virus particle attachment to host bacterial cells

  2024cites this paper
• Bacteriophages and Their Host Range in Multidrug-Resistant Bacterial Disease Treatment

  2023cites this paper
• Bacteriophage Therapy for Pan-Drug-Resistant Pseudomonas aeruginosa in Two Persons With Cystic Fibrosis

  2023cites this paper
• Rapid assessment of changes in phage bioactivity using dynamic light scattering

  2023cites this paper
• Rapid assessment of changes in phage bioactivity using dynamic light scattering

  2023cites this paper